SARTORIUS STEDIM BIOTECH (56S1.DE) Fundamental Analysis & Valuation

FRA:56S1 • FR0013154002

Current stock price

164.35 EUR
-6.9 (-4.03%)
Last:

This 56S1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. 56S1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 56S1 was profitable.
  • In the past year 56S1 had a positive cash flow from operations.
  • 56S1 had positive earnings in each of the past 5 years.
  • Each year in the past 5 years 56S1 had a positive operating cash flow.
56S1.DE Yearly Net Income VS EBIT VS OCF VS FCF56S1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • The Return On Assets of 56S1 (3.33%) is worse than 63.16% of its industry peers.
  • 56S1's Return On Equity of 6.50% is in line compared to the rest of the industry. 56S1 outperforms 42.11% of its industry peers.
  • With a Return On Invested Capital value of 6.11%, 56S1 perfoms like the industry average, outperforming 57.89% of the companies in the same industry.
  • 56S1 had an Average Return On Invested Capital over the past 3 years of 5.23%. This is below the industry average of 9.34%.
  • The last Return On Invested Capital (6.11%) for 56S1 is above the 3 year average (5.23%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.33%
ROE 6.5%
ROIC 6.11%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
56S1.DE Yearly ROA, ROE, ROIC56S1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • The Profit Margin of 56S1 (8.96%) is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of 56S1 has declined.
  • 56S1's Operating Margin of 17.72% is fine compared to the rest of the industry. 56S1 outperforms 63.16% of its industry peers.
  • In the last couple of years the Operating Margin of 56S1 has declined.
  • 56S1 has a better Gross Margin (45.33%) than 63.16% of its industry peers.
  • 56S1's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 17.72%
PM (TTM) 8.96%
GM 45.33%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
56S1.DE Yearly Profit, Operating, Gross Margins56S1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. 56S1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so 56S1 is destroying value.
  • Compared to 1 year ago, 56S1 has about the same amount of shares outstanding.
  • The number of shares outstanding for 56S1 has been increased compared to 5 years ago.
  • Compared to 1 year ago, 56S1 has an improved debt to assets ratio.
56S1.DE Yearly Shares Outstanding56S1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
56S1.DE Yearly Total Debt VS Total Assets56S1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • An Altman-Z score of 3.78 indicates that 56S1 is not in any danger for bankruptcy at the moment.
  • 56S1 has a better Altman-Z score (3.78) than 73.68% of its industry peers.
  • 56S1 has a debt to FCF ratio of 8.69. This is a slightly negative value and a sign of low solvency as 56S1 would need 8.69 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 8.69, 56S1 perfoms like the industry average, outperforming 47.37% of the companies in the same industry.
  • A Debt/Equity ratio of 0.49 indicates that 56S1 is not too dependend on debt financing.
  • 56S1 has a better Debt to Equity ratio (0.49) than 63.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 8.69
Altman-Z 3.78
ROIC/WACC0.66
WACC9.26%
56S1.DE Yearly LT Debt VS Equity VS FCF56S1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.3 Liquidity

  • 56S1 has a Current Ratio of 1.02. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.02, 56S1 is doing worse than 63.16% of the companies in the same industry.
  • 56S1 has a Quick Ratio of 1.02. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 56S1 has a Quick ratio of 0.53. This is in the lower half of the industry: 56S1 underperforms 68.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.53
56S1.DE Yearly Current Assets VS Current Liabilites56S1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. 56S1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.71% over the past year.
  • Measured over the past 5 years, 56S1 shows a small growth in Earnings Per Share. The EPS has been growing by 1.13% on average per year.
  • 56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 6.74%.
  • The Revenue has been growing by 9.21% on average over the past years. This is quite good.
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%

3.2 Future

  • 56S1 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.04% yearly.
  • 56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.26% yearly.
EPS Next Y19.6%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
EPS Next 5Y19.04%
Revenue Next Year7.44%
Revenue Next 2Y9.02%
Revenue Next 3Y9.46%
Revenue Next 5Y11.26%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
56S1.DE Yearly Revenue VS Estimates56S1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
56S1.DE Yearly EPS VS Estimates56S1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. 56S1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 37.35, which means the current valuation is very expensive for 56S1.
  • Compared to the rest of the industry, the Price/Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 73.68% of the companies listed in the same industry.
  • The average S&P500 Price/Earnings ratio is at 25.23. 56S1 is valued slightly more expensive when compared to this.
  • Based on the Price/Forward Earnings ratio of 31.23, the valuation of 56S1 can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of 56S1 indicates a slightly more expensive valuation: 56S1 is more expensive than 73.68% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of 56S1 to the average of the S&P500 Index (22.42), we can say 56S1 is valued slightly more expensively.
Industry RankSector Rank
PE 37.35
Fwd PE 31.23
56S1.DE Price Earnings VS Forward Price Earnings56S1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 56S1 is valued a bit more expensive than 73.68% of the companies in the same industry.
  • 56S1's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 53.5
EV/EBITDA 21.48
56S1.DE Per share data56S1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as 56S1's earnings are expected to grow with 19.05% in the coming years.
PEG (NY)1.91
PEG (5Y)33.11
EPS Next 2Y19.98%
EPS Next 3Y19.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. 56S1.DE Dividend Analysis

5.1 Amount

  • 56S1 has a yearly dividend return of 0.40%, which is pretty low.
  • In the last 3 months the price of 56S1 has falen by -20.18%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • Compared to an average industry Dividend Yield of 0.56, 56S1 has a dividend in line with its industry peers.
  • With a Dividend Yield of 0.40, 56S1 pays less dividend than the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 0.4%

5.2 History

  • The dividend of 56S1 is nicely growing with an annual growth rate of 15.19%!
Dividend Growth(5Y)15.19%
Div Incr Years0
Div Non Decr Years1
56S1.DE Yearly Dividends per share56S1.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1

5.3 Sustainability

  • 25.24% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
  • The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.24%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
56S1.DE Yearly Income VS Free CF VS Dividend56S1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
56S1.DE Dividend Payout.56S1.DE Dividend Payout, showing the Payout Ratio.56S1.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

56S1.DE Fundamentals: All Metrics, Ratios and Statistics

SARTORIUS STEDIM BIOTECH

FRA:56S1 (3/20/2026, 7:00:00 PM)

164.35

-6.9 (-4.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)N/A
Inst Owners11.98%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.00B
Revenue(TTM)2.97B
Net Income(TTM)265.80M
Analysts78.95
Price Target247.39 (50.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.4%
Yearly Dividend0.69
Dividend Growth(5Y)15.19%
DP25.24%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.48%
Min EPS beat(2)-12.72%
Max EPS beat(2)-2.24%
EPS beat(4)2
Avg EPS beat(4)4.36%
Min EPS beat(4)-12.72%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.28%
EPS beat(12)3
Avg EPS beat(12)-11.72%
EPS beat(16)3
Avg EPS beat(16)-14.26%
Revenue beat(2)0
Avg Revenue beat(2)-4.06%
Min Revenue beat(2)-4.17%
Max Revenue beat(2)-3.94%
Revenue beat(4)2
Avg Revenue beat(4)-1.07%
Min Revenue beat(4)-4.17%
Max Revenue beat(4)3.52%
Revenue beat(8)4
Avg Revenue beat(8)-1.65%
Revenue beat(12)5
Avg Revenue beat(12)-1.63%
Revenue beat(16)6
Avg Revenue beat(16)-1.17%
PT rev (1m)0.22%
PT rev (3m)2.79%
EPS NQ rev (1m)-1.22%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.39%
EPS NY rev (3m)-1.16%
Revenue NQ rev (1m)-5.86%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.28%
Revenue NY rev (3m)-2.98%
Valuation
Industry RankSector Rank
PE 37.35
Fwd PE 31.23
P/S 5.39
P/FCF 53.5
P/OCF 23.11
P/B 3.91
P/tB N/A
EV/EBITDA 21.48
EPS(TTM)4.4
EY2.68%
EPS(NY)5.26
Fwd EY3.2%
FCF(TTM)3.07
FCFY1.87%
OCF(TTM)7.11
OCFY4.33%
SpS30.49
BVpS42.03
TBVpS-3.39
PEG (NY)1.91
PEG (5Y)33.11
Graham Number64.5
Profitability
Industry RankSector Rank
ROA 3.33%
ROE 6.5%
ROCE 8%
ROIC 6.11%
ROICexc 6.56%
ROICexgc 23.58%
OM 17.72%
PM (TTM) 8.96%
GM 45.33%
FCFM 10.08%
ROA(3y)3.15%
ROA(5y)7.45%
ROE(3y)7.54%
ROE(5y)16.68%
ROIC(3y)5.23%
ROIC(5y)11.87%
ROICexc(3y)5.56%
ROICexc(5y)12.62%
ROICexgc(3y)18.67%
ROICexgc(5y)31.48%
ROCE(3y)6.85%
ROCE(5y)15.55%
ROICexgc growth 3Y-18%
ROICexgc growth 5Y-10.32%
ROICexc growth 3Y-31.81%
ROICexc growth 5Y-17.24%
OM growth 3Y-16.3%
OM growth 5Y-7.16%
PM growth 3Y-29.07%
PM growth 5Y-12.64%
GM growth 3Y-4.79%
GM growth 5Y-2.9%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF 8.69
Debt/EBITDA 2.39
Cap/Depr 123.61%
Cap/Sales 13.25%
Interest Coverage 3.42
Cash Conversion 82.03%
Profit Quality 112.49%
Current Ratio 1.02
Quick Ratio 0.53
Altman-Z 3.78
F-Score7
WACC9.26%
ROIC/WACC0.66
Cap/Depr(3y)145.19%
Cap/Depr(5y)180.27%
Cap/Sales(3y)14.18%
Cap/Sales(5y)13.22%
Profit Quality(3y)157.37%
Profit Quality(5y)116.81%
High Growth Momentum
Growth
EPS 1Y (TTM)25.71%
EPS 3Y-20.14%
EPS 5Y1.13%
EPS Q2Q%8.74%
EPS Next Y19.6%
EPS Next 2Y19.98%
EPS Next 3Y19.05%
EPS Next 5Y19.04%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-5.29%
Revenue growth 5Y9.21%
Sales Q2Q%2.78%
Revenue Next Year7.44%
Revenue Next 2Y9.02%
Revenue Next 3Y9.46%
Revenue Next 5Y11.26%
EBIT growth 1Y41.93%
EBIT growth 3Y-20.72%
EBIT growth 5Y1.39%
EBIT Next Year55.74%
EBIT Next 3Y26.51%
EBIT Next 5Y22.89%
FCF growth 1Y-37.09%
FCF growth 3Y18.06%
FCF growth 5Y3.02%
OCF growth 1Y-15.08%
OCF growth 3Y4.17%
OCF growth 5Y10.67%

SARTORIUS STEDIM BIOTECH / 56S1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to 56S1.DE.


Can you provide the valuation status for SARTORIUS STEDIM BIOTECH?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.


How profitable is SARTORIUS STEDIM BIOTECH (56S1.DE) stock?

SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for 56S1 stock?

The Price/Earnings (PE) ratio for SARTORIUS STEDIM BIOTECH (56S1.DE) is 37.35 and the Price/Book (PB) ratio is 3.91.


What is the earnings growth outlook for SARTORIUS STEDIM BIOTECH?

The Earnings per Share (EPS) of SARTORIUS STEDIM BIOTECH (56S1.DE) is expected to grow by 19.6% in the next year.